← Back to Search

MRI Scans for Preventive Healthcare (Hercules Trial)

N/A
Recruiting
Led By Perry Kaneriya, MD, MBA
Research Sponsored by Hercules
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be >=18 years of age at the time of enrollment
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 10 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will involve studying up to 100,000 adult men and women in the United States using whole-body magnetic resonance imaging (WB-MRI). Participants will be recruited at different clinical sites and need

Who is the study for?
This study is for adults over 18 interested in advanced preventive healthcare who can pay for their own WB-MRI scan. Participants must be able to provide medical history, follow study procedures like staying still during the MRI, and understand consent forms.
What is being tested?
The trial is observing how well whole-body MRI scans can predict significant health issues such as nervous system disorders, cancer, aneurysms, neurological and metabolic diseases in a general population.
What are the potential side effects?
MRI scans are generally safe but may cause discomfort due to loud noises or claustrophobia. Some people might experience dizziness or a metallic taste if they have metal in their body.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 10 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 10 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Primary Endpoint and 5-point scale of CSD (Clinically Significant Disease) of CSD diagnosed post-baseline in general population subjects.
Secondary study objectives
Secondary Endpoint of ONCO-RADS Score (Oncological relevant findings reporting and data system) diagnosed in the follow-up period, including but not limited to, types of cancers, aneurysms, metabolic disorders, neurologic disorders, renal function, etc

Side effects data

From 2021 Phase 2 trial • 7 Patients • NCT01585402
100%
Diarrhea
71%
Fatigue
71%
Myalgia
71%
Nausea
71%
Arthralgia
57%
Hypernatremia
57%
Vomiting
43%
Headache
43%
Anemia
43%
Dizziness
43%
Dysgeusia
43%
Hypertriglyceridemia
43%
Palpitations
43%
Sinus bradycardia
43%
Back pain
43%
Flu like symptoms
29%
Constipation
29%
Dental caries
29%
Weight loss
29%
Bloating
29%
Abdominal pain
29%
Skin infection
29%
Gastroesophageal reflux disease
29%
Cholesterol high
29%
Anxiety
29%
Upper respiratory infection
29%
Paresthesia
29%
Anorexia
29%
Neck pain
29%
Dyspepsia
29%
Alanine aminotransferase increased
29%
Weight gain
29%
Bone pain
29%
Rash maculo-papular
29%
Hematuria
29%
Hypertension
14%
Dysphagia
14%
Lymphocyte count decreased
14%
Dry mouth
14%
Esophagitis
14%
Aspartate aminotransferase increased
14%
Left inguinal hernia surgery
14%
Fracture
14%
Osteoporosis
14%
Gastritis
14%
Hypercalcemia
14%
Hyperkalemia
14%
Pain in extremity
14%
Urinary tract infection
14%
External iliac artery stenosis
14%
Jump graft on the bypass area declining function of previous graft
14%
Stroke
14%
Lung infection
14%
Periodontal disease
14%
Toothache
14%
Depression
14%
Vivid dreams
14%
Sore throat
14%
Creatinine increased
14%
Calcaneus spur
14%
Joint inflammation/pain
14%
Pelvic pain
14%
Cold symptoms
14%
Strep agalactiae Urinary tract infection
14%
Malaise
14%
Memory impairment
14%
Syncope
14%
Elevated urine phosphorus
14%
Renal calculi
14%
Urinary frequency
14%
Arthralgia flare swelling of right hand
14%
Arthralgia flare swelling of right wrist
14%
Swelling of finger on fourth MCP of right hand
14%
Non-cardiac chest pain
14%
Pain
14%
Streptococcus pyogenes
14%
Premature atrial contractions
14%
Chest pain - cardiac
14%
Cough
14%
Dyspnea
14%
Postnasal drip
14%
White blood cell decreased
14%
Flank pain
14%
Ear pain
14%
Presyncope
14%
Somnolence
14%
Edema limbs
14%
Hemorrhoids
14%
Injection site reaction
14%
Lower gastrointestinal hemorrhage
14%
Hypocalcemia
14%
Hypercholesterolemia
14%
Hyperphosphatemia
14%
Left atrial enlargement; Incomplete right bundle branch block
14%
Sinus tachycardia
14%
Allergic reaction
14%
Pain of skin
14%
Blister on right 4th toe
14%
Dry eye
14%
Laryngitis
14%
Hemoglobinuria
14%
Skin ulceration
14%
Hyperparathyroidism
14%
Hypotension
14%
Blurred vision
100%
80%
60%
40%
20%
0%
Study treatment Arm
Etidronate Treatment for Arterial Calcifications Due to Deficiency in CD73 (ACDC)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: MRI Scan ArmExperimental Treatment1 Intervention
Whole Body MRI Scan
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MRI Scan
2012
Completed Phase 2
~1420

Find a Location

Who is running the clinical trial?

HerculesLead Sponsor
Prenuvo IncUNKNOWN
Pratik Shingru, MBBS, MPHStudy DirectorHercules research center
Perry Kaneriya, MD, MBAPrincipal InvestigatorHercules
~66667 spots leftby Jan 2034
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top